BR9206313A - Anticorpos recombinantes para terapia humana. - Google Patents

Anticorpos recombinantes para terapia humana.

Info

Publication number
BR9206313A
BR9206313A BR9206313A BR9206313A BR9206313A BR 9206313 A BR9206313 A BR 9206313A BR 9206313 A BR9206313 A BR 9206313A BR 9206313 A BR9206313 A BR 9206313A BR 9206313 A BR9206313 A BR 9206313A
Authority
BR
Brazil
Prior art keywords
recombinant antibodies
human therapy
therapy
human
recombinant
Prior art date
Application number
BR9206313A
Other languages
English (en)
Inventor
Roland A Newman
Nabil Hanna
Ronald W Raab
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27112830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9206313(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of BR9206313A publication Critical patent/BR9206313A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR9206313A 1991-07-25 1992-07-24 Anticorpos recombinantes para terapia humana. BR9206313A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73506491A 1991-07-25 1991-07-25
US85628192A 1992-03-23 1992-03-23
PCT/US1992/006194 WO1993002108A1 (en) 1991-07-25 1992-07-24 Recombinant antibodies for human therapy

Publications (1)

Publication Number Publication Date
BR9206313A true BR9206313A (pt) 1995-04-11

Family

ID=27112830

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9206313A BR9206313A (pt) 1991-07-25 1992-07-24 Anticorpos recombinantes para terapia humana.

Country Status (24)

Country Link
EP (3) EP0605442B1 (pt)
JP (1) JP3048640B2 (pt)
KR (1) KR0137806B1 (pt)
AP (1) AP307A (pt)
AT (2) ATE237638T1 (pt)
AU (1) AU673499B2 (pt)
BG (1) BG62656B1 (pt)
BR (1) BR9206313A (pt)
CA (1) CA2114015C (pt)
CZ (1) CZ289472B6 (pt)
DE (2) DE69233628T2 (pt)
DK (2) DK1266965T3 (pt)
ES (2) ES2265005T3 (pt)
FI (1) FI117703B (pt)
HU (2) HUT70272A (pt)
IL (1) IL102640A0 (pt)
MY (1) MY121185A (pt)
NO (1) NO318097B1 (pt)
NZ (1) NZ243706A (pt)
OA (1) OA09879A (pt)
PT (1) PT100735B (pt)
RO (1) RO116404B1 (pt)
SK (2) SK285960B6 (pt)
WO (1) WO1993002108A1 (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DE69233104T2 (de) * 1991-07-15 2004-05-13 The Wellcome Foundation Ltd., Greenford Herstellung von Antikörpern
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
ATE195428T1 (de) * 1994-04-26 2000-09-15 Kanebo Ltd Arznei für rheumatoide arthritis
DE69519997T2 (de) * 1994-10-25 2001-06-21 Glaxo Group Ltd., Greenford Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
CA2206471A1 (en) * 1994-12-07 1996-06-13 Hoffmann-La Roche Inc. Monoclonal antibody fragments having immunosuppressant activity
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US6893636B2 (en) 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
JP2002512776A (ja) * 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP2990054A1 (en) 1998-08-11 2016-03-02 Biogen Inc. Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
PT2055313E (pt) 1998-11-09 2015-08-25 Biogen Idec Inc Tratamento de malignidades hematológicas associadas a células tumorais em circulação utilizando anticorpo quimérico anti-cd20
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU2001271614B2 (en) * 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
ES2389141T3 (es) * 2000-07-03 2012-10-23 Catalent Pharma Solutions, Llc Células huésped que contienen vectores de integración múltiple
AU7025201A (en) 2000-07-03 2002-01-14 Gala Design Inc Expression vectors
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
CA2543631A1 (en) * 2003-11-07 2005-05-26 Amgen Inc. Monkey immunoglobulin sequences
AU2004291107B2 (en) 2003-11-14 2010-09-30 Brigham And Women's Hospital, Inc. Methods of modulating immunity
KR100942849B1 (ko) 2004-03-30 2010-02-17 글락소 그룹 리미티드 면역글로불린
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
KR101446025B1 (ko) * 2005-08-03 2014-10-01 아이바이오, 인크. 면역글로불린의 생산을 위한 조성물 및 방법
KR20080068004A (ko) * 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
NZ565904A (en) * 2005-08-15 2012-02-24 Cephalon Australia Pty Ltd Chimeric antibodies with New World primate CDR regions
EP1969010A4 (en) 2005-12-20 2009-07-22 Peptech Ltd ANTIBODY TO ANOTHER ANTI-INFLAMMATORY DOMAIN
CN103232540A (zh) 2006-02-01 2013-08-07 赛法隆澳大利亚控股有限公司 结构域抗体构建体
EP2056858B1 (en) 2006-08-11 2014-06-25 CSL Limited Treatment of pulmonary disease conditions
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
WO2008031056A2 (en) 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
PL2068921T3 (pl) 2006-10-19 2014-12-31 Csl Ltd Przeciwciała o dużym powinowactwie będące antagonistami receptora alfa1 interleukiny 13
US8613925B2 (en) 2006-10-19 2013-12-24 Csl Limited Anti-IL-13Rα1 antibodies and their uses thereof
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EP2331140B1 (en) 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
KR102188544B1 (ko) 2010-11-30 2020-12-08 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
JP2015500775A (ja) * 2011-10-31 2015-01-08 エムベラ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 片手操作可能なパッケージ
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
CA3049114A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Antibody fragments for the treatment of biofilm-related disorders
AU2017396503A1 (en) 2017-01-30 2019-07-11 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Psoriatic arthritis
WO2018147915A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CA3114925A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
CA3145385A1 (en) 2019-07-08 2021-01-14 Steven D. Goodman Antibody compositions for disrupting biofilms
US20240301070A1 (en) 2020-06-04 2024-09-12 Bioinvent International Ab Improving antibody tolerability associated with intravenous administration
EP4288068A1 (en) 2021-03-09 2023-12-13 BioInvent International AB Novel combinations of antibodies and uses thereof
WO2023161448A1 (en) * 2022-02-24 2023-08-31 Abnomx Bv Human-like target-binding proteins
TW202336033A (zh) 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233104T2 (de) * 1991-07-15 2004-05-13 The Wellcome Foundation Ltd., Greenford Herstellung von Antikörpern

Also Published As

Publication number Publication date
CA2114015C (en) 2002-12-10
PT100735A (pt) 1993-10-29
DE69233011T2 (de) 2003-11-06
SK8894A3 (en) 1994-09-07
KR0137806B1 (ko) 1998-04-30
BG62656B1 (bg) 2000-04-28
ATE237638T1 (de) 2003-05-15
ES2196002T3 (es) 2003-12-16
EP0605442B1 (en) 2003-04-16
CZ14994A3 (en) 1994-07-13
EP1266965A2 (en) 2002-12-18
MY121185A (en) 2006-01-28
SK285960B6 (sk) 2007-12-06
AU673499B2 (en) 1996-11-14
NO940219D0 (no) 1994-01-21
SK285046B6 (sk) 2006-05-04
NO318097B1 (no) 2005-01-31
JP3048640B2 (ja) 2000-06-05
NO940219L (no) 1994-03-25
AU2425592A (en) 1993-02-23
EP1266965B1 (en) 2006-05-24
DK0605442T3 (da) 2003-08-04
ES2265005T3 (es) 2007-02-01
AP307A (en) 1994-01-31
HU9400201D0 (en) 1994-05-30
HU211881A9 (en) 1995-12-28
DE69233628D1 (de) 2006-06-29
EP1715045A2 (en) 2006-10-25
EP0605442A4 (en) 1995-07-12
HUT70272A (en) 1995-09-28
RO116404B1 (ro) 2001-01-30
CZ289472B6 (cs) 2002-01-16
DK1266965T3 (da) 2006-09-25
OA09879A (en) 1994-09-15
WO1993002108A1 (en) 1993-02-04
NZ243706A (en) 1994-08-26
EP1715045A3 (en) 2006-12-13
DE69233011D1 (de) 2003-05-22
EP0605442A1 (en) 1994-07-13
EP1266965A3 (en) 2003-01-02
IL102640A0 (en) 1993-01-14
FI940336A0 (fi) 1994-01-24
FI117703B (fi) 2007-01-31
ATE327331T1 (de) 2006-06-15
FI940336A (fi) 1994-03-10
DE69233628T2 (de) 2007-04-26
BG98411A (bg) 1995-02-28
CA2114015A1 (en) 1993-02-04
AP9200413A0 (en) 1992-07-31
PT100735B (pt) 1999-07-30
JPH06509708A (ja) 1994-11-02

Similar Documents

Publication Publication Date Title
BR9206313A (pt) Anticorpos recombinantes para terapia humana.
BR9610404A (pt) Anticorpos anti-cd4 recombinantes para terapia humana
DE68921798D1 (de) Therapeutische Nuleoside.
FI903656A0 (fi) Terapeutiska kinuklidinfoereningar.
FI894688A (fi) Flytande oralt tagbart terapeutiskt system.
DE3889062D1 (de) Monoklonaler Antikörper gegen humanen BCDF.
DE69214558D1 (de) Krebstherapiesystem
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
FI893897A0 (fi) Terapeutiska nukleosider.
FI934588A (fi) Insulinlik vaextfaktor bindande protein haerstammande fraon maenniskoben
FI923486A0 (fi) Terapeutiska aemnen.
FI894321A0 (fi) Terapeutiska aemnen.
DE3687542D1 (de) Monoklonaler antikoerper gegen humanes protein c.
FI920701A0 (fi) Anordning foer terapeutisk tryck- behandling.
FI910753A (fi) Terapeutiska nukleocider.
FI923528A (fi) Terapeutiska aemnen.
DK149591A (da) Proteinpraeparat
DK175091D0 (da) Human tumor associated antigens, ca-ou2 and ca-ou3
ZA925615B (en) Recombinant antibodies for human therapy
DK147891D0 (da) Proteinpraeparat
ES1004875Y (es) Nuevo vendaje terapeutico.

Legal Events

Date Code Title Description
EE Request for examination
FC Decision: refusal
EG Technical examination (opinion): publication of technical examination (opinion)
HIFC Refusal cancelled
FC Decision: refusal
CKFC Appeal: appeal against refusal
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/18 (2006.01), C07K 16/00 (2006.0